BridgeBio Pharma, Inc.

# BridgeBio Pharma, Inc.

A commercial-stage biopharmaceutical company, BridgeBio discovers, develops, and commercializes medicines targeting genetic diseases and cancers. The company's portfolio includes Attruby, an oral small molecule TTR stabilizer approved for transthyretin amyloid cardiomyopathy (ATTR-CM), along with multiple candidates in clinical development. These include low-dose infigratinib for achondroplasia and hypochondroplasia in pediatric populations, Encaleret for autosomal dominant hypocalcemia type 1 in Phase 3 trials, and BBP-418 for limb-girdle muscular dystrophy in Phase 3 development. The company also maintains a pipeline addressing mendelian disorders, oncology indications, and gene therapy approaches.

BridgeBio operates through internal discovery and development programs supported by collaborations and licensing agreements with academic and commercial partners, including Novartis, Alexion Pharma, and Stanford University. The company is headquartered in Palo Alto, California, and operates as a Delaware corporation listed on the Nasdaq. With approximately 725 full-time employees, BridgeBio operates primarily within the United States while pursuing a development strategy focused on rare genetic conditions with well-defined patient populations and established clinical endpoints.